文献速递放射性药物与辐射防护核素与放射性配体治疗

HIV感染患者肺外结核治疗过程中前瞻性系列FDG PET/CT:一项探索性研究

Prospective Serial FDG PET/CT During Treatment of Extrapulmonary Tuberculosis in HIV-Infected Patients: An Exploratory Study.
PubMed 文献 · Clin Nucl Med · 2018-01-01

该前瞻性探索性研究对18例HIV/结核患者于基线、治疗2个月及结核治疗结束时行FDG PET/CT,评估其作为治疗反应监测工具的价值。治疗2个月后78%患者出现显著代谢反应,淋巴结代谢反应异质(57%淋巴结病灶SUVmax下降、41%无变化);治疗结束时95%患者活动性淋巴结大幅反应(SUVmax平均下降85%、中位100%),但仅47%达完全代谢反应。作者认为FDG PET/CT是潜在监测工具,应在更大研究中探索。

要点

  • 18例HIV/结核患者行基线、2个月及治疗结束FDG PET/CT。
  • 2个月时78%患者显著代谢反应,淋巴结反应异质。
  • 治疗结束95%患者活动性淋巴结大幅反应,仅47%完全代谢反应。

核心结论

  • 在HIV患者肺外结核这类难治情形中,FDG PET/CT是监测结核治疗反应的潜在工具,应在更大研究中探索。

研究设计与样本

  • 前瞻性探索性研究,纳入18例HIV/结核患者,于基线、治疗2个月(PET-2)及结核治疗结束时(PET-3)行FDG PET/CT,并将FDG摄取演变与患者临床结局相关联。

主要发现

  • 治疗2个月后,78%的患者出现显著代谢反应。

关键数值与推荐

  • 治疗2个月后,淋巴结代谢反应异质:57%的淋巴结部位SUVmax下降,41%的淋巴结部位FDG摄取无变化。
  • 除淋巴结外的其他器官显示更均匀的反应。
  • 结核治疗结束时FDG PET/CT显示所有感染器官完全反应,95%的患者活动性淋巴结呈大幅反应(SUVmax平均下降85%,中位100%)。
  • 结核治疗后仅47%的患者见完全代谢反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为探索性研究,作者结论指出FDG PET/CT应在更大研究中探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to prospectively describe evolution of F-FDG uptake of extrapulmonary tuberculosis (TB) throughout the course of TB treatment in HIV patients to evaluate F-FDG PET/CT as a monitoring tool of treatment response. METHODS: We performed baseline FDG PET/CT, PET-2 after 2 months, and PET-3 at the end of TB treatment in 18 HIV/TB patients. We correlated evolution of FDG uptake with clinical outcome of patients. RESULTS: After 2 months of treatment, 78% of the patients had a significant metabolic response. Lymph node (LN) metabolic response was heterogeneous, with 57% of LN sites showing decreased SUVmax and 41% showing unchanged FDG uptake. Organs other than LNs showed more homogeneous response. The FDG PET/CT performed at the end of TB treatment showed a complete response of all infected organs and a drastic response in terms of active LNs in 95% of the patients (SUVmax mean decrease = 85%, median = 100%). A complete metabolic response after TB treatment was seen in only 47% of patients. CONCLUSIONS: In difficult-to-treat entities such as extrapulmonary TB in HIV patients, FDG PET/CT is a potential tool in monitoring TB treatment response and should be explored in larger studies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Martin C, Castaigne C, Vierasu I, et al. Prospective Serial FDG PET/CT During Treatment of Extrapulmonary Tuberculosis in HIV-Infected Patients: An Exploratory Study. Clin Nucl Med. 2018. PMID: 30015658. doi:10.1097/RLU.0000000000002187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。